Management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with solid tumours, lymphoma or multiple myeloma: a French national observational study (The OncoBOS study).

Trial Profile

Management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with solid tumours, lymphoma or multiple myeloma: a French national observational study (The OncoBOS study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Therapeutic Use
  • Acronyms OncoBos
  • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Status changed from active, no longer recruiting to completed, according to the results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top